Hepatocellular Carcinoma Market Size
Hepatocellular carcinoma market size was valued at USD 2.72 Billion in 2024 and is expected to reach USD 10.03 Billion by 2034, growing at a CAGR of 15.4%.
Hepatocellular carcinoma represents the most frequent form of primary liver cancer, amounting to up to 90% of cases. It most frequently appears in the context of cirrhosis and chronic liver disease. Aflatoxin-related toxins, alcohol-related liver disease, chronic viral hepatitis, hepatitis B and C, and NAFLD are major risk factors for the development of HCC. Men are more likely than women to get HCC, and it is more common in areas like Southeast Asia and sub-Saharan Africa, where hepatitis B infection is very contagious. In the pathophysiology of HCC, genetic and environmental factors interact in a highly complex way. Repeated cycles of cell death and regeneration linked to chronic inflammation and liver cell destruction may ultimately lead to a build-up of genetic alterations. This may promote the malignant transformation of hepatocytes by inducing the activation of oncogenes or the inactivation of tumor suppressor genes. When HCC tumors progress, they may appear as a single mass or several nodules, or they may be dispersed throughout the liver. The main underlying risk factors for HCC are typically the focus of prevention strategies, which also include hepatitis B vaccination, antiviral treatment for chronic viral hepatitis, moderation in alcohol intake, and management of metabolic risk factors that contribute to nonalcoholic fatty liver disease. Aflatoxin exposure from food treatments may lower the incidence of HCC in some groups. However, as our understanding of the biology of HCC advances, these novel focused prevention measures and tailored therapy techniques offer hope for better management against this tenacious enemy.